Afficher la notice abrégée

dc.contributor.authorCubo Nava, Ana María 
dc.contributor.authorHuélamo Moruno, Marta
dc.contributor.authorMartín-Seisdedos, María Carmen
dc.contributor.authorHernández-Hernández, Estrella
dc.contributor.authorLapresa-Alcalde, María Victoria
dc.contributor.authorRodríguez Martín, María de la O 
dc.contributor.authorDoyagüe Sánchez, María José 
dc.contributor.authorSayagués Manzano, José María 
dc.date.accessioned2024-01-29T15:26:51Z
dc.date.available2024-01-29T15:26:51Z
dc.date.issued2022-03-08
dc.identifier.citationCubo AM, Huélamo M, Martín-Seisdedos MC, Hernández-Hernández E, Lapresa-Alcalde MV, Rodríguez-Martín MO, Doyague MJ, Sayagués JM. Contingent cfDNA Screening Implementation: Increasing Diagnostic Accuracy and Reducing Invasive Testing - 6 Years' Results in a Single Center. Fetal Diagn Ther. 2022;49(3):103-113. doi: 10.1159/000523848. Epub 2022 Mar 8. PMID: 35259749.es_ES
dc.identifier.issn1015-3837
dc.identifier.otherPMID: 35259749.
dc.identifier.urihttp://hdl.handle.net/10366/154941
dc.description.abstract[EN]Objectives: Universal screening for trisomy using cell-free DNA (cfDNA) has proven to be more effective than combined test, but it is not cost efficient currently. Contingent cfDNA screening on the results of the first-trimester combined test can improve the detection rate of the combined test and reduce the number of invasive tests at a lower cost than universal screening. In 2018, a contingent screening program was implemented in the community of Castilla y Leon (Spain). This study aims to compare the results achieved in Salamanca University Hospital during the first 3 years of contingent screening (2018-2020) with those of the previous 3 years (2015-2017) to assess the changes in the trisomy detection rate and the number of invasive tests. Methods: A total of 9,903 singleton pregnancies without malformations nor nuchal translucency >p99 were included. 5,165 patients underwent combined screening and 4,738 had contingent screening based on the combined test risk. In the combined test group, women were offered an invasive test if the risk was ≥1:270, while risks under 1:270 were considered low risks, and no further testing was offered. In the contingent screening group, invasive testing was offered if the risk was ≥1:100 (≥1:50 from 2020 onwards), while cfDNA was offered if the combined test risk was between 1:100 and 1:1,000 (1:50-1:1,000 from 2020 onwards). When risk was <1:1,000, no further testing was offered. Aneuploidies detected by cfDNA were confirmed by invasive diagnostic testing. Results: There were 33 cases of trisomy 21 (T21) throughout the 6 years of study. Four cases had low/intermediate risks and were spotted by cfDNA. Risk >1:1,000 threshold for contingent test detected 100% T21. There was a false-positive result for trisomy 13. There were no false-negative results. "No-call" cfDNA results were minimized by repeating blood collection 2 weeks later, as fetal fraction (FF) was doubled. Invasive testing had a drop rate of 84% after contingent screening implementation. Discussion: The implementation of population-based contingent screening significantly reduces the number of invasive tests without lowering diagnostic accuracy. To achieve the maximum efficiency of the program, it is important to know the best cut-offs according to the population where the program is to be implemented. The number of uninformative results due to low FF can be reduced by repeating the test 2 weeks after the initial extraction: this increases the FF to twice the initial one, achieving informative results and avoiding unnecessary invasive tests.es_ES
dc.language.isoenges_ES
dc.publisherKarger Publisherses_ES
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internacional
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subjectAmniocentesises_ES
dc.subjectCell-free DNAes_ES
dc.subjectCirculating fetal cell-free DNAes_ES
dc.subjectContingent screeninges_ES
dc.subjectInvasive testinges_ES
dc.subjectNoninvasive prenatal testinges_ES
dc.subject.meshAmniocentesis *
dc.subject.meshPrenatal Diagnosis *
dc.titleContingent cfDNA screening implementation: increasing diagnostic accuracy and reducing invasive testing - 6 years' results in a single centeres_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.relation.publishversionhttps://doi.org/10.1159/000523848
dc.identifier.doi10.1159/000523848
dc.rights.accessRightsinfo:eu-repo/semantics/openAccesses_ES
dc.identifier.essn1421-9964
dc.journal.titleFetal Diagnosis and Therapy
dc.volume.number49
dc.issue.number3
dc.page.initial103
dc.page.final113
dc.subject.decsamniocentesis *
dc.subject.decsdiagnóstico prenatal *


Fichier(s) constituant ce document

Thumbnail

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée

Attribution-NonCommercial-NoDerivatives 4.0 Internacional
Excepté là où spécifié autrement, la license de ce document est décrite en tant que Attribution-NonCommercial-NoDerivatives 4.0 Internacional